Plozasiran for Managing Persistent Chylomicronemia and Pancreatitis Risk

医学 急性胰腺炎 优势比 胃肠病学 高甘油三酯血症 安慰剂 内科学 临床终点 甘油三酯 胰腺炎 入射(几何) 载脂蛋白B 置信区间 随机对照试验 内分泌学 胆固醇 病理 光学 物理 替代医学
作者
Gerald F. Watts,Robert S. Rosenson,Robert A. Hegele,Ira J. Goldberg,Antonio Gallo,Ann C. Mertens,Alexis Baass,Rong Zhou,Ma’an Muhsin,Jennifer Hellawell,Nicholas J. Leeper,Daniel Gaudet
出处
期刊:The New England Journal of Medicine [Massachusetts Medical Society]
被引量:40
标识
DOI:10.1056/nejmoa2409368
摘要

BackgroundPersistent chylomicronemia is a genetic recessive disorder that is classically caused by familial chylomicronemia syndrome (FCS), but it also has multifactorial causes. The disorder is associated with the risk of recurrent acute pancreatitis. Plozasiran is a small interfering RNA that reduces hepatic production of apolipoprotein C-III and circulating triglycerides.MethodsIn a phase 3 trial, we randomly assigned 75 patients with persistent chylomicronemia (with or without a genetic diagnosis) to receive subcutaneous plozasiran (25 mg or 50 mg) or placebo every 3 months for 12 months. The primary end point was the median percent change from baseline in the fasting triglyceride level at 10 months. Key secondary end points were the percent change in the fasting triglyceride level from baseline to the mean of values at 10 months and 12 months, changes in the fasting apolipoprotein C-III level from baseline to 10 months and 12 months, and the incidence of acute pancreatitis.ResultsAt baseline, the median triglyceride level was 2044 mg per deciliter. At 10 months, the median change from baseline in the fasting triglyceride level (the primary end point) was −80% in the 25-mg plozasiran group, −78% in the 50-mg plozasiran group, and −17% in the placebo group (P<0.001). The key secondary end points showed better results in the plozasiran groups than in the placebo group, including the incidence of acute pancreatitis (odds ratio, 0.17; 95% confidence interval, 0.03 to 0.94; P=0.03). The risk of adverse events was similar across groups; the most common adverse events were abdominal pain, nasopharyngitis, headache, and nausea. Severe and serious adverse events were less common with plozasiran than with placebo. Hyperglycemia with plozasiran occurred in some patients with prediabetes or diabetes at baseline.ConclusionsPatients with persistent chylomicronemia who received plozasiran had significantly lower triglyceride levels and a lower incidence of pancreatitis than those who received placebo. (Funded by Arrowhead Pharmaceuticals; PALISADE ClinicalTrials.gov number, NCT05089084.)
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
暴躁小龙发布了新的文献求助10
刚刚
张润泽完成签到 ,获得积分10
刚刚
1秒前
文档发布了新的文献求助10
1秒前
2秒前
4秒前
5秒前
5秒前
6秒前
7秒前
7秒前
烟花应助zwk采纳,获得10
9秒前
蔡芝艳关注了科研通微信公众号
9秒前
YI完成签到,获得积分10
12秒前
12秒前
大个应助科研通管家采纳,获得10
13秒前
13秒前
充电宝应助科研通管家采纳,获得10
14秒前
SYLH应助科研通管家采纳,获得20
14秒前
Ava应助科研通管家采纳,获得10
14秒前
丘比特应助科研通管家采纳,获得10
14秒前
情怀应助科研通管家采纳,获得10
14秒前
Hello应助科研通管家采纳,获得10
14秒前
Owen应助科研通管家采纳,获得10
14秒前
14秒前
su发布了新的文献求助10
16秒前
钟垠州完成签到 ,获得积分10
16秒前
16秒前
活力的妙之完成签到 ,获得积分10
16秒前
丘比特应助只想困瞌睡采纳,获得10
16秒前
小宋发布了新的文献求助10
17秒前
笃定发布了新的文献求助30
19秒前
淡墨完成签到,获得积分10
20秒前
今后应助清漪采纳,获得10
20秒前
zwk发布了新的文献求助10
21秒前
24秒前
鹿君浩发布了新的文献求助10
25秒前
25秒前
小宋完成签到,获得积分10
26秒前
呵呵哒完成签到,获得积分20
27秒前
高分求助中
A new approach to the extrapolation of accelerated life test data 1000
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 500
‘Unruly’ Children: Historical Fieldnotes and Learning Morality in a Taiwan Village (New Departures in Anthropology) 400
Indomethacinのヒトにおける経皮吸収 400
Phylogenetic study of the order Polydesmida (Myriapoda: Diplopoda) 370
基于可调谐半导体激光吸收光谱技术泄漏气体检测系统的研究 350
Robot-supported joining of reinforcement textiles with one-sided sewing heads 320
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3989297
求助须知:如何正确求助?哪些是违规求助? 3531418
关于积分的说明 11253893
捐赠科研通 3270097
什么是DOI,文献DOI怎么找? 1804884
邀请新用户注册赠送积分活动 882087
科研通“疑难数据库(出版商)”最低求助积分说明 809158